Mieux dépister la stéatose hépatique en médecine de ville

Hypothèse formelle

Implementing a primary care-based panel management pathway that integrates FIB-4 and cardiometabolic risk assessment will increase the proportion of NAFLD patients with appropriate fibrosis monitoring or referral by 25-40% at 12 months, compared to usual care, because it systematically applies risk stratification and proactive outreach.

Titre donné par l’affûteur : Adapting Primary Care Panel Management for Non-Invasive NAFLD Risk Stratification: A Cluster Randomized Trial

Contre-preuves

1. Suggests that FIB-4 thresholds may not need to be adjusted for age, which could complicate risk stratification in elderly populations, but does not contradict the overall hypothesis.

   Gravité mineureAge-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care (2024)

Inconnues et conditions de validité

Inconnues identifiées

• The optimal age-adjusted FIB-4 thresholds for different age groups.
• The long-term impact of the pathway on clinical outcomes such as cirrhosis or mortality.
• Potential barriers to implementation in diverse primary care settings.

Conditions de validité

• Primary care clinics must have EHR capabilities to support FIB-4 calculation and patient tracking.Justification : The intervention relies on EHR prompts and panel management tools.
• FIB-4 thresholds must be age-adjusted (e.g., >1.3 for <65 years, >2.0 for ≥65 years) to avoid misclassification.Justification : FIB-4 performance varies with age; age-adjusted thresholds improve diagnostic accuracy.
• The intervention is limited to patients with NAFLD defined by imaging or biopsy, and without other liver diseases.Justification : The pathway is specific to NAFLD; other etiologies may require different management.

Mécanisme proposé

Chaîne causale

1. Step 1: Primary care staff receive training on NAFLD risk stratification using FIB-4 and cardiometabolic risk factors.
2. Step 2: Electronic health record (EHR) prompts trigger FIB-4 calculation for at-risk patients (e.g., with diabetes, obesity, or elevated ALT).
3. Step 3: Patients with FIB-4 >1.3 (or age-adjusted thresholds) are flagged for proactive outreach and scheduled for shared decision-making visits.
4. Step 4: During visits, patients receive lifestyle counseling and, if indicated, referral to hepatology or further non-invasive testing (e.g., elastography).
5. Step 5: Panel management ensures follow-up and tracking of patients, leading to higher rates of appropriate monitoring/referral.

Postulats clés

• FIB-4 is a valid and reliable non-invasive marker for fibrosis risk in primary care populations.
• Primary care staff can be trained to implement the pathway with fidelity.
• EHR prompts are effectively integrated into clinical workflows.
• Patients are willing to attend shared decision-making visits.

Cadre théorique

Chronic Care Model and Risk Stratification in Primary Care

Variables

Prédictions falsifiables

1. 1

   The proportion of NAFLD patients with appropriate fibrosis monitoring or referral at 12 months will be 25-40% higher in the intervention group compared to usual care.

   Borne quantitative

   Absolute increase of 25-40 percentage points (e.g., from 20% to 45-60%)

   Méthode de mesure

   Chart review or EHR extraction to determine if patients received FIB-4 testing, elastography, hepatology referral, or follow-up within 12 months.Test statistique Mixed-effects logistic regression with random effects for cluster (clinic), adjusting for baseline covariates, alpha=0.05

   Hypothèse nulle

   H0: There is no difference in the proportion of patients with appropriate monitoring/referral between intervention and control groups.

Protocole expérimental

Références

10 références, toutes issues de Semantic Scholar. Une référence vérifiée est un article qui existe et qui est indexé par Semantic Scholar. Cela ne veut pas dire qu’il confirme l’idée.

1. 1
   F. Kanwal, J. Shubrook, L. Adams et al. (2021). Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.appui direct · 480 citations · doi:10.1053/j.gastro.2021.07.049Ce qu’en retient le documentaliste Describes a stepwise approach using non-invasive tests to identify patients with clinically significant fibrosis, supporting the integration of such pathways into primary care.Pertinence Provides a detailed clinical care pathway for NAFLD risk stratification and management, which aligns with the proposed adaptation of primary care frameworks.
2. 2
   T. Davyduke, P. Tandon, Mustafa Al-Karaghouli et al. (2019). Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care.appui direct · 77 citations · doi:10.1002/hep4.1411Ce qu’en retient le documentaliste A staged risk-stratification model using FIB-4 and VCTE could save up to 87% of further assessments and improve accessibility by moving initial fibrosis evaluation to the medical home.Pertinence Demonstrates the feasibility and impact of using FIB-4 as a first-line triage tool in primary care, supporting the proposed use of non-invasive fibrosis scores in primary care workflows.
3. 3
   E. B. Tapper, M. Hunink, N. Afdhal et al. (2016). Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.appui direct · 55 citations · doi:10.1371/journal.pone.0147237Ce qu’en retient le documentaliste Risk-stratification of patients with NAFLD in primary care clinic is a cost-effective strategy that should be formally explored in clinical practice.Pertinence Shows that risk stratification of NAFLD in primary care is cost-effective, supporting the economic viability of the proposed integrated pathway.
4. 4
   A. Shaheen, K. Riazi, A. Medellin et al. (2020). Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study..appui direct · 35 citations · doi:10.9778/cmajo.20200009Ce qu’en retient le documentaliste Implementation of a primary care-accessible SWE pathway for patients with NAFLD facilitated fibrosis risk stratification and greatly reduced hepatology referrals.Pertinence Provides evidence that a primary care-accessible pathway using shear wave elastography can effectively risk-stratify NAFLD patients and reduce referrals, supporting the feasibility of such integrated pathways.
5. 5
   E. Tsochatzis, P. Newsome (2018). Non-alcoholic fatty liver disease and the interface between primary and secondary care..appui indirect · 127 citations · doi:10.1016/S2468-1253(18)30077-3Ce qu’en retient le documentaliste Highlights the need for robust pathways for risk stratification in primary care, with subsequent referrals as required.Pertinence Discusses the need for robust pathways for risk stratification in primary care, supporting the premise that primary care is the appropriate setting for NAFLD management.
6. 6
   V. Wong, S. Zelber-Sagi, K. Cusi et al. (2022). Management of NAFLD in primary care settings.appui indirect · 77 citations · doi:10.1111/liv.15404Ce qu’en retient le documentaliste Primary care physicians are in a pivotal position to provide quality care for NAFLD patients, including lifestyle intervention and management of comorbidities.Pertinence Reviews the role of primary care in NAFLD management, supporting the idea that primary care is pivotal in managing NAFLD and its comorbidities.
7. 7
   K. Cusi, S. Isaacs, D. Barb et al. (2022). American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)..appui indirect · 836 citations · doi:10.1016/j.eprac.2022.03.010Ce qu’en retient le documentaliste Provides evidence-based recommendations for the diagnosis and management of NAFLD in primary care, including the use of non-invasive fibrosis scores.Pertinence Provides guidelines for NAFLD management in primary care, supporting the integration of non-invasive tests and risk stratification in primary care settings.
8. 8
   Davide Golinelli, Valentina Pecoraro, Dario Tedesco et al. (2025). Population risk stratification tools and interventions for chronic disease management in primary care: a systematic literature review.appui par analogie · 22 citations · doi:10.1186/s12913-025-12690-0Ce qu’en retient le documentaliste Risk stratification tools can be used to tailor interventions and proactively manage high-risk individuals with chronic diseases in primary care, though effects vary.Pertinence Provides evidence on the use of risk stratification tools in primary care for chronic diseases, supporting the transferability of such approaches to NAFLD.
9. 9
   Pimsiri Sripongpun, W. Kim, A. Mannalithara et al. (2022). The Steatosis-Associated Fibrosis Estimator (SAFE) Score: A Tool to Detect Low-Risk Non-Alcoholic Fatty Liver Disease in Primary Care.appui direct · 83 citations · doi:10.1002/hep.32545Ce qu’en retient le documentaliste The SAFE score uses widely available variables to estimate liver fibrosis and may be used in primary care to recognize low-risk NAFLD.Pertinence Develops and validates a non-invasive score for use in primary care to identify low-risk NAFLD, supporting the use of simple clinical indicators for risk stratification.
10. 10
    P. Golabi, V. Isakov, Z. Younossi (2023). Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness..appui indirect · 30 citations · doi:10.1016/j.cld.2023.01.001Ce qu’en retient le documentaliste Considering the asymptomatic nature of undiagnosed NAFLD, high suspicion and noninvasive diagnosis have utmost importance especially in primary care level.Pertinence Highlights the asymptomatic nature of NAFLD and the importance of high suspicion and noninvasive diagnosis in primary care, supporting the need for proactive screening.

Nouveauté

Score de nouveauté : 0,80 sur 1 · Verdict : jugée nouvelle

Ce score est attribué par un agent à partir des travaux trouvés. C’est une estimation, pas une mesure. Comment ce score est produit

Travaux les plus proches

• Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease (2021)Différence avec l’idée : This paper proposes a clinical care pathway for NAFLD risk stratification, but does not explicitly frame it as an adaptation of primary care’s panel management approach for chronic diseases like diabetes.
• Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care (2019)Différence avec l’idée : This paper evaluates a FIB-4 first strategy in primary care, but does not explicitly link it to the broader primary care chronic disease management model (e.g., panel management, shared decision-making).

Lacunes et données

Lacunes identifiées

• Need for implementation research on how to integrate NAFLD screening into existing primary care workflows, including EHR integration and provider training.
• Need for studies evaluating the effectiveness of shared decision-making in NAFLD management in primary care.

Données disponibles

• Data from the NASH Clinical Research Network observational study (used in SAFE score development).
• Data from the cross-sectional study implementing SWE pathway in primary care (Shaheen et al., 2020).

Synthèse du panel

Note de consensus : 6,52/10 Moyenne des cinq notes, pondérée par la confiance que chaque relecteur déclare.

Verdict du méta-relecteur : publier

Points d’accord

• The hypothesis addresses a significant clinical gap in NAFLD management and proposes a pragmatic, scalable intervention using existing EHR infrastructure and FIB-4.
• The phased validation approach (in silico, pilot, full trial) is well-structured and reduces risk, making it attractive to funders and feasible for implementation.

Points de désaccord

• The expected effect size of 25-40% is considered optimistic by some reviewers, while others see it as plausible given the intervention’s systematic approach.
• The potential for low fidelity due to alert fatigue and workflow barriers is a major concern for the Contrarian, but other reviewers believe it can be mitigated with proper training and process evaluation.

Chemin critique

The success of this hypothesis hinges on the fidelity of implementation in real-world primary care settings, particularly overcoming alert fatigue and ensuring consistent adoption of the panel management pathway.

Recommandation finale

The panel recommends proceeding with the pilot phase to gather preliminary data on feasibility and fidelity, while addressing methodological gaps such as contamination prevention, sample size calculation with ICC, and robust outcome ascertainment. The full cluster trial should be contingent on successful pilot results and a clear plan for process evaluation. The intervention shows promise for improving NAFLD care, but its real-world impact depends on overcoming implementation barriers.